Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients

Wilson Disease Clinical Trial

— VARCUWIC  

Official title:

Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients Treated With Chelators or Zinc Salts

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06430359
• Other study ID #: 69HCL23_1227
• Status: Not yet recruiting
• Start date: July 1, 2024
• Est. completion date: August 1, 2025

Study information

• Verified date: May 2024
• Source: Hospices Civils de Lyon
• Contact: Eduardo COUCHONNAL, Dr
• Phone: 04 27 35 70 50
• Email: eduardo.couchonnal-bedoya[@]chu-lyon.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Wilson's disease (WD) is a genetic disorder characterized by an accumulation of copper in the body, mainly in the liver and brain. Patients suffering from this disease are monitored by liver function tests, blood copper levels, and 24-hour urinary copper determinations.

Treatment is based either on chelating the copper accumulated in the body using D-penicillamine or Trientine or on limiting intestinal copper absorption with zinc salts.

Monitoring copper elimination in urine collected over 24 hours is essential for estimating a patient's copper load, adapting treatment dosage, and detecting any copper deficiency.

Nevertheless, urine collection is often complicated for patients, given the obvious constraints of collecting urine over 24 hours. Without this, clinical decisions are usually made based on spot urine.

There is no official recommendation for monitoring urinary copper elimination other than on 24-hour urine.

According to studies on healthy volunteers under physiological conditions, urinary copper elimination occurs according to a circadian rhythm, with minimal copper elimination between 8 pm and 4 am and maximum between 8 am and noon.

The study would aim to find the period of the day best correlated with 24h urinary copper excretion

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: August 1, 2025
• Est. primary completion date: August 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients with a confirmed diagnosis of Wilson's Disease (Leipzig score ?4).

• Age = 6 years and =70 years.

• Patient able to perform 24h urine.

• Current treatment with D-Pencillamine, Trientine or Zinc.

• Non-opposition of patient and/or legal representatives for minor patients.

Exclusion Criteria:

• Patients who had a change in treatment within the last 6 months before the inclusion

• Patients who have undergone liver transplantation

• Patients with known chronic renal failure (GFR < 30 ml/min)

• Patients on long-term diuretic or corticosteroid therapy

• Persons deprived of liberty by a judicial or administrative decision

• Patient under judicial protection, unable to express consent

Related Conditions & MeSH terms

• Wilson Disease

Intervention

Diagnostic Test:
• urine and blood test
3 urine collections of an 8h period. One blood sample for liver function test and copper assessment

Locations

Country	Name	City	State
France	Service de Gastroentérologie, Hépatologie et Nutrition Pédiatriques - Hôpital Femme Mère Enfant	Bron	Rhone

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation factor	Correlation between 24-hour urinary copper excretion and 8-hour urinary copper excretion collected between midnight and 8 am).	Two 24-hour urine recollection